Atibuclimab, CAS 2417175-94-9

Product Description: Atibuclimab, is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab can be used for the research of amyotrophic lateral sclerosis[1]. Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist[2].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Henderson RD, Agosti JM, McCombe PA, et al. Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis. Medicine (Baltimore). 2021;100(42):e27421. /[2]Verbon A, et al. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol. 2001;166(5):3599-3605.

CAS Number: 2417175-94-9

Molecular Weight: N/A

Compound Purity: 97.74

Research Area: Inflammation/Immunology

Solubility: H2O

Target: Others

• Artikelnummer: MEXHY-P99008-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99008-1
• Green Labware: Nein
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK